当前位置: 首页 >> 检索结果
3. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
作者: Julio Rosenstock.;Stanley Hsia.;Luis Nevarez Ruiz.;Sarah Eyde.;David Cox.;Wen-Shuo Wu.;Rong Liu.;Jianghao Li.;Laura Fernández Landó.;Max Denning.;Lisa Ludwig.;Yanyun Chen.; .
来源: N Engl J Med. 2025年
Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management. Additional data on the efficacy and safety of orforglipron are needed.
5. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
作者: W Timothy Garvey.;Matthias Blüher.;Cynthia Karenina Osorto Contreras.;Melanie J Davies.;Eva Winning Lehmann.;Kirsi H Pietiläinen.;Domenica Rubino.;Paolo Sbraccia.;Thomas Wadden.;Niels Zeuthen.;John P H Wilding.; .
来源: N Engl J Med. 2025年
Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg has shown promising results in early-phase trials; the efficacy of the combination (known as CagriSema) on weight loss in persons with either overweight and coexisting conditions or obesity is unknown.
6. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
作者: Melanie J Davies.;Harpreet S Bajaj.;Christa Broholm.;Astrid Eliasen.;W Timothy Garvey.;Carel W le Roux.;Ildiko Lingvay.;Christian Bøge Lyndgaard.;Julio Rosenstock.;Sue D Pedersen.; .
来源: N Engl J Med. 2025年
Cagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema) for weight management in adults with type 2 diabetes, including those in a subgroup who are undergoing continuous glucose monitoring.
8. Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes.
作者: Trevor W Reichman.;James F Markmann.;Jon Odorico.;Piotr Witkowski.;John J Fung.;Martin Wijkstrom.;Fouad Kandeel.;Eelco J P de Koning.;Anne L Peters.;Chantal Mathieu.;Leslie S Kean.;Bote G Bruinsma.;Chenkun Wang.;Molly Mascia.;Bastiano Sanna.;Gautham Marigowda.;Felicia Pagliuca.;Doug Melton.;Camillo Ricordi.;Michael R Rickels.; .
来源: N Engl J Med. 2025年
Zimislecel is an allogeneic stem cell-derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed.
15. Three Cases of Vertical Transmission of Clade Ib Mpox Virus.
作者: Emmanuel Hasivirwe Vakaniaki.;Nono-Raymond Swar Kuispond.;Yuichiro Hirata.;Eugene Bangwen.;Isabel Brosius.;Eddy Kinganda-Lusamaki.;Seiya Ozono.;Harutaka Katano.;Laurent Gabanga Ndunge.;Noella Mulopo-Mukanya.;Jean-Claude Tshomba.;Elise De Vos.;Christophe Van Dijck.;Papy Munganga.;Guy Mukari.;Yves Mujula.;Divin Mazambi Mambo.;Steeven Bilembo Kitwanda.;Nadine Maliyamungu-Bubala.;Léandre Mutimbwa-Mambo.;Ian Crozier.;Lori E Dodd.;Olivier Tshiani-Mbaya.;Bienvenu Massamba Lebwaze.;Espoir Bwenge Malembaka.;Isaac Barhishindi.;Susanne Krasemann.;Robert Colebunders.;Patrick D M C Katoto.;Sheila Makiala-Mandanda.;Jason Kindrachuk.;Anne W Rimoin.;Jean-Jacques Muyembe-Tamfum.;Daniel Mukadi-Bamuleka.;Tony Wawina-Bokalanga.;Sabin Sabiti Nundu.;Tadaki Suzuki.;Raphaël Bulakali Chirimwami.;Laurens Liesenborghs.;Placide Mbala-Kingebeni.
来源: N Engl J Med. 2025年392卷23期2385-2387页 16. Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer.
作者: Ramaprasad Srinivasan.;Sandeep Gurram.;Eric A Singer.;Abhinav Sidana.;Munjid Al Harthy.;Mark W Ball.;Julia C Friend.;Lisa Mac.;Erin Purcell.;Cathy D Vocke.;Christopher J Ricketts.;Heidi H Kong.;Edward W Cowen.;Ashkan A Malayeri.;Joanna H Shih.;Maria J Merino.;W Marston Linehan.
来源: N Engl J Med. 2025年392卷23期2346-2356页
Hereditary leiomyomatosis and renal-cell cancer (HLRCC) is an inherited disorder characterized by germline pathogenic variants in the gene encoding fumarate hydratase and an increased risk of papillary renal-cell carcinoma. No effective therapy is known for patients with advanced HLRCC-associated papillary renal-cell carcinoma, and most patients die from progressive disease.
|